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Abstract
Introduction: Polymorphic variants in the 5p15, 6p12, 6p21, and 15q25 loci were demonstrated to potentially contribute to
lung cancer carcinogenesis. Therefore, this study was performed to assess the role of those variants in non-small cell lung
cancer (NSCLC) risk and prognosis in a Portuguese population.
Materials and Methods: Blood from patients with NSCLC was prospectively collected. To perform an association study, DNA
from these patients and healthy controls were genotyped for a panel of 19 SNPs using a SequenomH MassARRAY platform.
Kaplan-Meier curves were used to assess the overall survival (OS) and progression-free survival (PFS).
Results: One hundred and forty-four patients with NSCLC were successfully consecutively genotyped for the 19 SNPs. One
SNP was associated with NSCLC risk: rs9295740 G/A. Two SNPs were associated with non-squamous histology: rs3024994
(VEGF intron 2) T/C and rs401681 C/T. Three SNPs were associated with response rate: rs3025035 (VEGF intron 7) C/T,
rs833061 (VEGF –460) C/T and rs9295740 G/A. One SNP demonstrated an influence on PFS: rs401681 C/T at 5p15, p = 0.021.
Four SNPs demonstrated an influence on OS: rs2010963 (VEGF +405 G/C), p = 0.042; rs3025010 (VEGF intron 5 C/T), p = 0.047;
rs401681 C/T at 5p15, p = 0.046; and rs31489 C/A at 5p15, p = 0.029.
Conclusions: Our study suggests that SNPs in the 6p12, 6p21, and 5p15 loci may serve as risk, predictive and prognostic
NSCLC biomarkers. In the future, SNPs identified in the genomes of patients may improve NSCLC screening strategies and
therapeutic management as well.
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Introduction
Lung cancer is an aggressive disease that affects more than
1.5 million people worldwide [1]. An American study estimated
that there were 226,160 lung cancer cases and 160,340 lung
cancer-related deaths for both sexes [2], corresponding to 29
and 14% of all cancer-related deaths in men and women,
respectively [2]. In 2008, approximately 3,000 new lung cancer
cases and approximately the same number of lung cancer-
related deaths were reported in Portugal [3,4]. Non-small cell
lung cancer (NSCLC) represent 85% of lung cancer cases [5].
Recently, a randomized trial demonstrated the superiority of
lung cancer screening using low-dose computed tomography
compared with standard X-rays and presented a 20% reduction
in death [6]. Thus, optimizing screening tools in a high-risk
population is important for clinicians attempting to reduce lung
cancer incidence and mortality.
Many risk factors are known to be responsible for lung cancer
susceptibility, including tobacco consumption [7], passive smoke
and occupational diseases [8,9]. Moreover, the genomic profile has
recently emerged as a major contributor to lung cancer
carcinogenesis [10–23]. In 2009, a genome-wide associated study
(GWAS) reported that a polymorphic variant in the 5p15.33 locus,
rs2736100 (TERT), was associated with lung adenocarcinoma
susceptibility [10]. In 2012, Ito et al. demonstrated that variants
located in the CHRNA5-CHRNA3-CHRNB4 cluster on chro-
mosome 15q25 (rs12914385, rs1317286, and rs931794) modified
the impact of cigarette smoking on lung cancer risk in a Japanese
population but demonstrated no statistically significant primary
effects on lung cancer risk [11]. Our group demonstrated the
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impact of epidermal growth factor +61 A/G polymorphisms
(located on chromosome 4q25–q27) on NSCLC risk in a
Portuguese population [13].
Angiogenesis is known to play a major role in NSCLC
carcinogenesis [5]. Vascular endothelial growth factor (VEGF)
and its receptor (VEGFR) are considered the main catalysts of new
vessel creation and tumor angiogenesis [24]. A recent systematic
review reported that many polymorphic variations in the 6p12 and
6p21 loci could contribute to serum VEGF expression modulation
and may thus influence tumor risk and prognosis [5]. Importantly,
current anti-angiogenic therapies[4,25–27], are in clinical use, and
the genetic make-up of patients, particularly the allelic variants of
the angiogenic proteins (e.g., VEGF and VEGFR), may modulate
the patient response to those therapies. Thus, considering all of the
paramount features of the polymorphic variations in the 5p15,
6p12, 6p21 and 15q25 loci and NSCLC tumor behavior, our
group conducted this study to assess the role of the genetic
polymorphisms in the 5p15, 6p12, 6p21 and 15q25 loci on NSCLC
risk, with a secondary aim of assessing the role of those variants in
patient outcome.
Materials and Methods
Design and Setting
A case-controlled/prospective study from February 2010 to
April 2011 was conducted in two central North Portugal Hospitals:
Sa˜o Joa˜o Hospital University Center, Porto, Portugal and Sa˜o
Marcos Hospital, Braga, Portugal. Laboratory studies were
centralized at the Life and Health Sciences Research Institute,
School of Health Sciences, University of Minho, Braga, Portugal.
Subjects
For the statistical preparation of this study, sample calculations
were performed prior to patient recruitment using the 95%
confidential interval (CI) formula, and we considered a genotype
proportion difference among cases and controls ranging from 10
to 20%. We used Piface software(http://homepage.stat.uiowa.
edu/˜rlenth/Power/) and estimated the sample number for
approximately 126 patients for a power .0.8 and a p,0.05.
The inclusion criteria for this study included patients with a
confirmed NSCLC diagnosis by histopathological examination,
more than 21 years old at admission, a recommendation for
treatment at participant’s institution, and informed consent after
explanation of the study’s features by one of the researchers.
All of the patient follow-up information was obtained by
consulting clinical records. The lung cancer patient median follow-
up was 12 months. For NSCLC risk assessment, a group of blood
donor controls were selected from a control set to match for
gender and adjust for age in the statistical analysis. The control
group had no follow-up information. Signed informed consent was
obtained from each participant. The Sa˜o Joa˜o University Hospital
Regional ethics committee approved this study. All patients and
controls involved in this study were Portuguese Caucasians.
First-line Treatment Data
Patients with advanced NSCLC with epidermal growth factor
receptor (EGFR) exon 19 and 21 mutations orally received 250 mg
of gefitinib once a day until disease progression was observed.
EGFR-negative patients with advanced NSCLC were treated with
a platinum-based regimen, according to clinical condition and
indications.
Table 1. Single nucleotide polymorphisms primers sequence of the study.
Locus Gene SNP Reverse Forward
5p15 TERT, CLPTM1L C/T rs4635969 ACGTTGGATGGAGATTAATGACAGGCCAAG ACGTTGGATGGCATTTTTTTTCCTTTTGG
CLPTM1L C/A rs31489 ACGTTGGATGACAGCGAGACCTTGTCTCAA ACGTTGGATGCTCGCATTCCACCTGTTTAC
CLPTM1L C/T rs401681 ACGTTGGATGAGGTCTGCTATCCAGACAAC ACGTTGGATGGCTCTCCAAAGTTGTCGTAG
CLPTM1L C/T rs402710 ACGTTGGATGTCTACCTGTACCAGCGGTG ACGTTGGATGCGGTGAAAGCCGTCATTCC
6p12 VEGF intron 7 C/T rs3025035 ACGTTGGATGGGTTTGTGTGAAGTGACCTG ACGTTGGATGTATTCCCAGATACAGCCAGC
VEGF +936 C/T rs3025039 ACGTTGGATGAGCACTTTGGGTCCGGAGG ACGTTGGATGATGGCGAATCCAATTCCAAG
VEGF 39-UTR T/C rs3025040 ACGTTGGATGATCCCCAAAGCACAGCAATG ACGTTGGATGAGATCACAGGTACAGGGATG
VEGF -2489 C/T rs1005230 ACGTTGGATGTCAGAGCCCCAACTTTGTTC ACGTTGGATGGCATATAGGAAGCAGCTTGG
VEGFA - 2578 C/A rs699947 ACGTTGGATGGTCAGTCTGATTATCCACC ACGTTGGATGTTCCCATTCTCAGTCCATGC
VEGF –460 C/T rs833061 ACGTTGGATGTTGGAATCCTGGAGTGACCC ACGTTGGATGTGTGGGTGAGTGAGTGTGTG
VEGF intron 2 A/G rs833070 ACGTTGGATGAAGTTCACAGCACCCGAACA ACGTTGGATGCCCTGGTTTGCATTCCTTTG
VEGF intron 5 C/T rs3025010 ACGTTGGATGCCCTTCAAGAGAACCAGAGC ACGTTGGATGCTTTCTTCCCTGTGACAGAC
VEGF intron 2 T/C rs3024994 ACGTTGGATGATGGGCACAGAATCCTTCTC ACGTTGGATGTCAGACTTCTAGTCTCGTTC
VEGF –7 C/T rs25648 ACGTTGGATGCACAGCCCGAGCCGGAGAG ACGTTGGATGGCACCCAAGACAGCAGAAAG
VEGF +405 G/C rs2010963 ACGTTGGATGCGGCGGTCACCCCCAAAAG ACGTTGGATGTCGAGGAAGAGAGAGACGG
6p21 vWF G/A rs9295740 ACGTTGGATGCACACAGCTCAATATGGTCC ACGTTGGATGGTGGACAGAAAGGCAGTTCA
15q25 CHRNA3 C/T rs12914385 ACGTTGGATGGCAAAAAAACAGAAGATGTC ACGTTGGATGGGCTCTATTTTTGTAGTTGC
LOC123688 T/C rs8034191 ACGTTGGATGCCACAAGTCCCCTTAGTTAC ACGTTGGATGGTAGTGGTTAGAGCCCAATG
AGPHD1 G/A rs931794 ACGTTGGATGGCTTGCTTGTGGTACTTTTG ACGTTGGATGGACAGAGCACATGAAATCCC
Abbreviations: SNP, single nucleotide polymorphisms; vWF, von Willebrand factor; VEGF, vascular endothelial growth factor; CHRNA3, cholinergic nicotine receptor
alpha3; VEGF 39-UTR, VEGF 39untranslated region; TERT, telomerase reverse transcriptase; CLPTM1L, cleft lip and palate transmembrane 1-like; AGPHD1, aminoglycoside
phosphotransferase domain containing 1.
doi:10.1371/journal.pone.0072373.t001
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Variable Considered
The following demographic and clinical data were collected: age
at admission, sex, ethnicity, histological diagnosis, TNM clinical
stage (according to the American joint committee on cancer
(AJCC) 2010 guidelines) [28,29], Eastern Cooperative Oncology
Group (ECOG) performance status score at admission [30],
smoking status, EGFR mutation status, pack-years of cigarette
consumption, overall survival (OS), and progression-free survival
(PFS). The systemic therapy response rate (RR) was assessed by
radiologists at our institution, according to (Response Evaluate
Criteria in Solid Tumor) RECIST guidelines version 1.1 [31].
Genotyping
DNA was extracted from the leukocytes of blood samples using
the commercial CitogeneH Blood Kit according to the manufac-
turer’s recommendations. [32] The extracted genomic DNA was
analyzed by agarose gel electrophoresis, quantified by nanodrop,
and stored at –70uC until use. The loci examined in this study are
summarized in Table 1. Genotyping of the allele-specific primer
extension products, which were generated from amplified DNA
sequences, was performed using the Sequenom MassARRAY
iPLEX Gold platform (Sequenom, San Diego, California) at the
Instituto Gulbenkian de Cieˆncias, Lisbon, Portugal. Primers were
designed using MassARRAY Assay Design 3.1 software (Seque-
nom, San Diego, California) and genotyping was performed by an
investigator who was blinded to the sample status (i.e., from case or
control subjects). The genotyping quality was assessed by duplicate
analysis of 10% of the samples, which demonstrated a 100%
agreement rate.
Statistical Analysis
X2 and Wilcoxon-Mann Whitney tests were used to compare
the frequency distribution of the age, sex, and genetic polymor-
phisms at the 5p15, 6p12, 6p21 and 15q25 loci and the allele
distribution among the cases and controls. Moreover, the X2 test
was used to verify that the observed allele distribution in the
control group was in Hardy-Weinberg equilibrium (HWE). The
odds ratio (OR) and 95% CI for the effect of the polymorphic
variants on the risk for NSCLC were estimated using univariate
and multivariate logistic regression analyses, which were adjusted
for sex and age as continuous variables. The false-positive report
probability (FPRP) was calculated for significant associations
observed in multivariate tests according to the study by Wacholder
and colleagues [33]. Furthermore, we analyzed OS and PFS using
Kaplan-Meier curves. All statistical tests were two-sided, and
significance was considered for p,0.05. Data analysis was
performed using IBMH SPSS Statistics, version 19.0.
Results
Patient’s Clinical-pathological Data
During the study period, we consecutively enrolled 144 patients
with NSCLC and 144 controls (Table 2). The median age was 61
years (range: 32–89) in the NSCLC group and 48 years (range:
35–65) in the control group. Tables 3 and 1S demonstrate the
relationship between the distribution of the polymorphic variant
allele frequencies in the control group and Hardy-Weinberg
equilibrium. All controls were in HWE. The sex distribution
proportions were the same among the patients with NSCLC and
controls (matched 1:1).
Susceptibility Assessment
By univariate and multivariate analyses adjusted for gender and
age (Tables 3 and 1S), we found a significant association between
rs9295740 G/A (6p21) and the overall NSCLC risk (OR=1.978,
95% CI: 1.076–3.636), which was mainly in males (OR=1.921,
95% CI: 0.942–3.919). We observed that the rs9295740 GA+AA
genotype group represented a nearly statistically significant
increase in NSCLC risk when compared with the rs9295740 AA
genotype group (OR=1.742, 95% CI: 0.979–3.098). Further-
more, we found a nearly statistically significant increase in the
overall NSCLC risk for the rs12914385 (CHRNA3) C/T
polymorphic variation (OR=1.835, 95% CI: 0.964–3.490) when
compared with the rs12914385 (CHRNA3) C/C variant(Table 3).
Moreover, the rs12914385 (CHRNA3) CT+TT genotype group
demonstrated a significant association with NSCLC risk
(OR=1.837, 95% CI: 1.002–3.369).
When assessing the association between the polymorphic
variants in the 5p15, 6p12, 6p21 and 15q25 loci and histological
subtype, we noted an association between the two genetic
polymorphisms rs3024994 (VEGF intron 2) T/C and rs401681
(CLPTM1L) C/T and the non-squamous histological subtype
(OR=5.315, 95% CI: 1.256–22.479 and OR=3.273, 95% CI:
1.006–10.648, respectively).
Table 2. Summary of clinical-pathological features of
subjects and controls.
Characteristics Cases Controls
Number 144 144
Gender
Male 78.5% 78.5%
Female 21.5% 21.5%
Age* 61.5 (32–89) 48 (35–65)
,41 years 2.8% 16%
.40 years 97.2% 84%
Smoke status
Current smoke 45.3% n.a
Ex - smoke 37.9% n.a
Never - smoke 16.8% n.a
Packs-year* 40 (0–240) n.a
Histology
Non-squamous 77.1% –
Squamous Cell 22.9% –
EGFR mutation
Positive 12.2% n.a.
Negative 87.8% n.a.
TNM stage –
I–IIIA 8.6% –
IIIB 12.4% –
IV 79% –
ECOG PS
0–2 88.6% 100%
3–4 11.4% 0.00
PFS (months) * 5 (3.95–6.40) n.a.
OS (months) * 10 (8.11–11.88) n.a.
Abbreviations: *median; EGFR – epidermal growth factor receptor; ECOG PS,
eastern cooperative oncology group performance status scale; n.a - not
assessed; OS, overall survival; PFS, progression-free-survival.
doi:10.1371/journal.pone.0072373.t002
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A FPRP calculation demonstrated that all of the above
mentioned significant polymorphism associations (i.e., rs9295740
(vWF G/A), rs12914385 (CHRNA3 C/T), rs3024994 (VEGF
intron 2 T/C), and rs401681 (CLPTM1L C/T)) remained
significant (FPRP#0.5) when a prior association probability
$10% was considered.
Predictive Biomarkers (First Line Regimen Response Rate)
Table 4 summarizes the relationships among the polymorphic
variations studied herein and NSCLC outcome mainly with
respect to the RR of the first-line regimen, PFS and OS. For the
5p15 locus, we found that the rs4635969 (TERT) CT+TT genotype
group had a 44.4% overall RR when compared with the
rs4635969 CC genotype, p=0.006(Table 4). We found that three
polymorphic variations in the 6p12 locus were predictive biomark-
ers for the overall platinum based regimen. The rs3025035 (VEGF
intron 7) CT genotype had a higher overall RR than the
rs3025035 (VEGF intron 7) CC genotype (72.2% versus 35.5%,
p=0.005). The rs833061 (VEGF –460) CT genotype had a slightly
lower RR than the rs833061 (VEGF –460) CC genotype (42.9%
versus 43.8%, p=0.036). The rs833070 (VEGF intron 2) AG+GG
genotype group had a little inner RR than the AA genotype group
(42.6% versus 43.8%, p=0.011). The rs9295740 G/A genotype in
the 6p21 locus had a higher overall RR than the rs9295740 GG
genotype (50% versus 41.8%, p=0.042; Table 4). We found no
predictive biomarkers for the first-line platinum based regimen in
the 15q25 locus.
Progression-free Survival
The overall PFS of the cohort was 5 months (range: 3.95–6.40).
The PFS and genetic polymorphism data are summarized in
Tables 4 and 2S. Only two loci had polymorphic variants with an
impact on PFS: rs9295740 G/A (6p21) and rs401681 C/T
(15q25). The rs9295740 GA genotype in the 6p21 locus demon-
strated a trend toward higher PFS than the rs9295740 GG and
rs9295740 AA genotypes: 6 months (range: 3.21–8.78) versus 4
months (range: 2.06–5.93) versus 4 months (range: 0.39–7.60),
respectively, p=0.074. However, the rs9295740 GA+AA genotype
group had a higher PFS than the rs9295740 GG genotype group:
6 months (range: 4.31–7.68) versus 4 months (range: 2.06–5.93),
respectively, p=0.034. The 5p15 locus rs401681 TT genotype had
a higher PFS than the rs401681 CC and rs401681 CT genotypes:
7 months (0.001–14.04) versus 2 months (range: 0.945–3.05)
versus 5 months (range: 3.22–6.77) months, respectively,
p=0.021(Figure 1A).
Overall Survival
The OS of the study population was 10 months (range: 8.11–
11.88). The polymorphic variants in the 6p12, 6p21 and 5p15 loci
were significantly associated with OS (Table 4). Two polymorphic
variants in the 6p12 locus were associated with OS. In only the
non-squamous histological subtype, the rs3025010 (VEGF intron 5)
CT genotype had a higher OS than the rs3025010 (VEGF intron
5) TT and rs3025010 (VEGF intron 5) CC genotypes: 13 months
(range: 9.63–16.36) versus 10 months (range: 0.0001–20.22) versus
6 months (range: 3.16–8.83), respectively, p=0.047(Figure 1B).
Table 3. Genotypes of the single nucleotide polymorphisms at 5p15, 6p12, 6p21, and 15q25 loci in lung cancer patients and
control subjects and their association with the risk of non-small-cell lung cancer adjusted for age and gender.
Chromosome region Genotype Control n (%) NSCLC n (%) NSCLC (OR, 95%CI) HWE (p value)
6p21 rs9295740 (vWF G/A)
GG 94 (65.3) 84 (58.3) –
GA 42 (29.2) 54 (37.5) 1.978 (1.076–3.636)
AA 8 (5.6) 6 (4.2) 0.814 (0.229–2.895) 0.263
GA+AA vs GG 50 (34.8) 60 (41.7) 1.742 (0.979–3.098)
Allele G 79.86 77.08
A 20.14 22.92
15q25 rs12914385 (CHRNA3 C/T)
CC 51 (35.4) 39 (27.1) –
CT 69 (47.9) 72 (50.0) 1.835 (0.964–3.490)
TT 24 (16.7) 33 (22.9) 1.844 (0.824–4.126) 0.935
CT+TT vs CC 93 (64.6) 105 (72.9) 1.837 (1.002–3.369)
Allele C 59.38 58.82
T 40.62 41.18
15q25 rs8034191 (LOC123688 T/C)
TT 53 (36.8) 44 (30.6) –
TC 67 (46.5) 71 (49.3) 1.785 (0.947–3.362)
CC 24 (16.7) 29 (20.1) 1.424 (0.635–3.195) 0.718
TC+CC vs TT 91 (63.2) 100 (69.4) 1.674 (0.925–3.032)
Allele T 60.07 61.39
C 39.93 38.61
Abbreviations: NSCLC, non-small-cell lung cancer; vWF, von Willebrand factor; CHRNA3, cholinergic nicotine receptor alpha3; HWE, Hardy-Weinberg equilibrium. In
HWE column p.0.05 stands for control group in HWE. Bold was used for highlight the almost statistical significance results and bold+gray for statistic significant
results.
doi:10.1371/journal.pone.0072373.t003
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Table 4. Genetic polymorphisms and non-small-cell lung cancer outcome (PFS, OS, RR for 1th line regimen).
Chromosome
region Genotype PFS (months)* P value OS (months)* P value
Positive
RR (%) P value
Positive RR (OR, 95%
CI)
5p15 rs4635969 C/T (TERT)
CC 5 (3.38–6.61) 9 (6.39–11.60) 41.4 –
CT 5 (1.94–8.05) 0.665 A 15 (9.17–20.83) 0.337 A 41.9 0.66C 1.036 (0.427–2.517)
TT 6 (0.001–16.73) 11 (0.265–21.73) 60.01 1.918 (0.290–12.672)
CT+TT vs CC 5 (2.21–7.78) 0.445 A 13 (8.82–17.17) 0.417 A 44.4 0.006C 1.129 (0.486–2.623)
rs31489 (CLPTM1L C/A)
CC 4 (1.89–6.10) 6 (1.104–10.896) 33.3 –
CA 6 (4.16–7.83) 0.588A 13 (6.33–19.66) 0.029 F 43.5 0.316 C 0.408 (0.122–1.360)
AA 6 (1.42–10.57) 13 (6.98–19.01) 55.6 0.625 (0.208–1.879)
CA+AA vs CC 6 (4.42–7.57) 0.449 A 13 (7.89–18.1) 0.008 F 46.9 0.216 C 0.571 (0.231–1.416)
rs401681 (CLPTM1L C/T)
CC 2 (0.945–3.05) 6 (3.02–8.97) 33.3
CT 5 (3.22–6.77) 0.021D 13 (8.61–17.38) 0.046A 43.1 0.442 C 1.488 (0.538–4.116)
TT 7 (0.001–14.04) 10 (5.10–14.89) 52.6 2.149 (0.620–7.455)
CT+TT vs CC 6 (4.5–7.49) 0.332A 11 (8.38–13.61) 0.021A 80 0.29 C 1.644 (0.620–4.359)
6p12 rs3025035 (VEGF intron 7
C/T)
CC 5 (3.55–6.44) 10 (7.28–12.71) 35.5 –
CT 8 (3.88–12.11) 0.282 A 12 (4.35–19.65) 0.472 A 72.2 0.005C 4.90 (1.56–15.37)
TT – – – –
rs833061 (VEGF –460 C/T)
CC 3 (0.0001–6.76) 9 (5.38–12.61) 43.8 –
CT 5 (3.82–6.18) 0.752 A 11 (8.47–13.52) 0.975 A 42.9 0.036 C 1.028 (0.331–3.196)
TT 5 (0.939–9.061) 10 (3.06–16.92) 40.9 0.967 (0.258–3.626)
CT+TT vs CC 5 (3.84–6.15) 0.469 A 10 (8.14–11.86) 0.902 A 42.3 0.011 C 1.011 (0.336–3.039)
rs833070 (VEGF intron 2
A/G)
AA 3 (0.82–5.18) 9 (2.09–15.90) 43.8 –
AG 6 (4.68–7.31) 0.424A 11 (8.05–13.94) 0.569 B 46 0.788C 1.172 (0.372–3.697)
GG 5 (2.64–7.35) 9 (3.77–14.22) 35.7 0.767 (0.216–2.728)
AG+GG vs AA 5 (3.83–6.17) 0.206A 10 (7.41–12.58) 0.471B 42.6 0.011C 1.011 (0.336–3.039)
rs3025010 (VEGF intron 5
C/T)
CC 4 (1.85–6.14) 6 (3.16–8.83) 38.1
CT 6 (4.35–7.64) 0.977A 13 (9.63–16.36) 0.047 D 41.5 0.307 C 1.163 (0.481–2.81)
TT 6 (1.01–10.98) 10 (0.0001–20.22) 63.6 2.733 (0.685–10.90)
CT+TT vs CC 6 (4.39–7.60) 0.883 A 13 (8.22–11.17) 0.020 F 46.2 0.530 C 1.393 (0.979–1.053)
rs2010963 (VEGF +405 G/
C)
GG 5 (3.1–6.89) 9 (4.17–13.82) 47.1 –
GC 5 (3.12–6.87) 0.463A 13 (8.70–17.29) 0.042 G 43.2 0.570 C 0.876 (0.354–2.164)
CC 5 (1.67–8.32) 3 (0.0001–8.88) 31.3 0.503 (0.143–1.771)
GC+CC vs GG 5 (2.98–7.01) 0.459 A 10 (5.56–14.43) 0.441 G 40 0.506 C 0.759 (0.324–1.779)
6p21 rs9295740 (vWF G/A)
GG 4 (2.06–5.93) 9 (5.91–12.08) 41.8 –
GA 6 (3.21–8.78) 0.074A 13 (8.4–17.59) 0.107 A 50 0.042 C 1.385 (0.584–3.285)
AA 4 (0.39–7.60) 11 (8.6–13.4) 0.0001 –
GA+AA vs GG 6 (4.31–7.68) 0.034 A 13 (9.38–16.61) 0.045 A 43.6 0.864 C 1.066 (0.464–2.452)
Abbreviations: * median; PFS, progression-free-survival; OS, overall survival; RR, response rate for 1th line therapy (complete, partial, stable); 95% CI, confidential
interval 95%.
Polymorphic Variants and NSCLC Biomarkers
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e72373
Furthermore, in only stages IIIB and IV, the rs2010963 (VEGF
+405) GC genotype had a higher OS than the rs2010963 (VEGF
+405) GG and rs2010963 (VEGF +405) CC genotypes: 13 months
(range: 8.70–17.29) versus 9 months (range: 4.17–13.82) versus 3
months (range: 0.0001–8.88), respectively, p=0.042(Figure 1C).
The rs9295740 GA+AA genotype group in the 6p21 locus had a
higher OS than the rs9295740 GG genotype group: 13 months
(range: 9.38–16.61) versus 9 months (range: 5.91–12.08),
p=0.045.
Two polymorphic variants were associated with OS in the 5p15
locus. We observed that in only the non-small histology subtype,
the rs31489 AA and rs31489 CA genotypes had a higher OS than
the rs31489 CC genotype: 13 months (range: 6.98–19.01) versus
13 months (range: 6.33–19.66) versus 6 months (range: 1.104–
10.896), respectively, p=0.029(Figure 1D and 1E). Moreover, the
rs401681 CT genotype had a higher OS than the rs401681 TT
and rs401681 CC genotypes: 13 months (range: 8.61–17.38)
versus 10 months (range: 5.10–14.89) versus 6 months (range:
3.02–8.97), respectively, p=0.046(Figure 1F).
Discussion
NSCLC Risk Biomarkers
In 2009, Landi et al. reported that nicotinic acetylcholine
receptor gene variants on chromosome 15q25 were associated
with an elevated overall lung cancer risk [10]. These single
nucleotide polymorphisms (SNPs) were also strongly associated
with all major histological groups of patients who were current and
former smokers [10]. In our study, the rs9295740 G/A genotype
(6p21) was associated with NSCLC risk in Portugal mainly in
males. In 2012, Bae et al. reported results from a Korean study
that assessed 1,094 Korean patients and 1,100 healthy controls
[12]. The authors did not find any association between rs9295740
G/A polymorphisms and lung cancer risk in a Korean population.
ALog rank test;
BBreslow test;
CChi square test;
DBreslow test (only non-squamous cell tumors);
ELog rank test (only stages IIIB and IV);
FLog rank test (only non-squamous cell tumors);
GBreslow test (only stages IIIB and IV). Bold was used for highlight almost statistical significance results and bold+gray for statistic significant results.;
adjusted for age.
doi:10.1371/journal.pone.0072373.t004
Table 4. Cont.
Figure 1. Progression-free survival (PFS) curve for the rs401681 C/T genetic polymorphism (A). Kaplan-Meir curve of the overall survival
(OS) for the rs3025010 (VEGF intron 5) C/T genetic polymorphisms (B). Kaplan-Meir curve of the overall survival (OS) for the rs2010963 (VEGF +405) G/
C genetic polymorphisms (C). Kaplan-Meir curve of the overall survival (OS) for the rs31489 C/A genetic polymorphisms (D). Kaplan-Meir curve of the
overall survival (OS) for the rs31489 CA+AA genotypes versus the rs31489 CC genotype (E). Kaplan-Meir curve of the overall survival (OS) for rs401681
C/T genetic polymorphisms (F).
doi:10.1371/journal.pone.0072373.g001
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This fact may be explained by divergences in the genomic
expression of different populations, as previously reported [34].
Furthermore, we found a trend for association with risk assessment
and conditions, including NSCLC risk in males and rs833061
(VEGF –460) C/T polymorphisms, overall NSCLC and
rs12914385 CHRNA3 C/T polymorphisms, overall NSCLC and
rs8034191 (LOC123688) T/C polymorphisms and NSCLC risk in
males and rs931794 G/A polymorphisms. Previous Asiatic studies
[11,12] also reported polymorphic variants in the 15q25 locus and
NSCLC risk, suggesting that instabilities in the 15q25 locus could
be a major mediator of lung cancer carcinogenesis. Though the
5p15 locus was previously reported [35] to be associated with lung
cancer susceptibility due to telomerase reverse transcriptase and
cleft lip and palate transmembrane 1-like gene effects, we could
not find an association between rs4635969 C/T polymorphisms
and NSCLC risk. In the 6p12 locus, we observed a nearly
statistically significant association between the rs833061 (VEGF –
460 C/T) polymorphism and NSCLC risk in males. In 2008, Zhai
et al. conducted a study that assessed 1,900 cases and 1,458
controls in a Caucasian population [17]. Zhai and colleagues
found no significant association between rs833061 and NSCLC,
suggesting that the 6p12 locus has no relationship with overall lung
cancer susceptibility. Nevertheless, our study demonstrated that
variants in the 6p12 and 15q25 loci such as rs3024994 (VEGF
intron 2) T/C and rs401681 C/T, respectively, were significantly
associated with non-squamous lung cancer histology risk. In 2012,
a Chinese group assessed 196 lung cancer patients and 229 healthy
controls [36]. This group found that multiple 5p15 variants
contributed to lung adenocarcinoma susceptibility [36].
NSCLC Predictive Biomarkers
EGFR mutations in exons 19 and 21 are the most effective,
predictive biomarkers of the response to EGFR TKIs for first-line
advanced NSCLC treatment [37,38]. In this context, finding novel
predictive biomarkers for overall systemic treatment remains a
challenge for clinicians and researchers. Moreover, three poly-
morphic variants in the 6p12 and 6p21 loci demonstrated a
significant influence on the overall response rate of first-line
systemic therapies regardless of the chosen regimen including
rs3025035 (VEGF intron 7) C/T, rs833061 (VEGF –460) C/T, and
rs9295740 G/A. These results may potentially lead to useful
biomarkers for therapeutic prediction. Importantly, these genetic
polymorphisms may be assessed using blood samples, increasing
their clinical application. Meanwhile, these findings may support
the idea that VEGF modulation may be a key player in lung
cancer carcinogenesis and aggressiveness, which was previously
suggested in pre-clinical and translational models [5,39].
NSCLC Prognostic Biomarkers
Our study also evaluated NSCLC prognosis by assessing the 19
SNPs and their relationship with PFS and OS. Our studied
demonstrated that a polymorphic variant in the 5p15 locus,
rs401681 C/T, was associated with the PFS of non-squamous cell
tumors. Previous reports [8] demonstrated that the histology
subtype of patients with NSCLC is associated with different
clinical behaviors among patients with NSCLC. We also found
that another polymorphic variant in 6p21, rs9295740 G/A,
demonstrated a nearly statistically significant influence on the PFS
for all patients with NSCLC. We found that four SNPs were
associated with the NSCLC overall survival (e.g., rs3025010
(VEGF intron 5) C/T (at 6p12), rs2010963 (VEGF +405) G/C (at
6p12), rs31489 C/A (at 5p15) and rs401681 C/T (at 5p15)). In
2008, Heist et al. [16] demonstrated that the rs2010963 (VEGF
+405) GC genotype was associated with better survival than the
GG and CC genotypes, which is in agreement with our results.
However, in 2010, Dong et al. [20] screened 54 SNPs in 568
Chinese patients with NSCLC and assessed the association of the
VEGF and EGFR genetic polymorphisms with NSCLC prognosis.
This study did not find an association between rs3025010 (VEGF
intron 5) C/T variants and NSCLC survival. GWAS [10,11] and
other studies [12,36,40] found that the 5p15 locus was associated
with lung cancer susceptibility, but none of those studies reported
concerns regarding overall survival. This is the first study to report
that polymorphic variants e.g., rs31489 C/A and rs401681 C/T,
in the 5p15 locus are associated with NSCLC overall survival and
patient prognosis in a Portuguese population.
Conclusions
Lung cancer management remains a challenge for researchers
and clinicians worldwide. The comprehensive understanding of
lung cancer biology is urgently needed. We believe that the results
presented in this study provide additional findings for NSCLC
understanding. We found that 1 SNP in the 6p21 locus is associated
with NSCLC risk, 1 SNP in the 6p12 locus and 1 SNP in the
15q25 locus is associated with non-squamous histology, 1 SNP at
5p15 is associated with PFS, 2 SNPs at 5p15 and 2 SNPs at 6p12
are associated with OS, 2 SNPs at 6p12 and 1 SNP at 6p21 are
associated with RR for first-line therapy. Our work suggests that
variants on chromosomes 5p15 and 6p21 are prognostic
biomarkers for advanced NSCLC. In addition, variants at 6p21
are NSCLC risk biomarkers, and variants at 6p12 and 6p21 are
predictive NSCLC biomarkers. In the future, SNPs identified in
the genomes of patients may improve NSCLC screening strategies
and therapeutic management.
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